Compare McDonald's Corp (MCD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs BIO-TECHNE Corp — how do they compare? McDonald's Corp trades at $273.03 (market cap $193.70B), while BIO-TECHNE Corp trades at $72.19 (market cap $11.24B). The key difference: McDonald's Corp is far larger — about 17.2× BIO-TECHNE Corp's market cap, and McDonald's Corp pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| MCD | TECH | |
|---|---|---|
Market Cap | $193.70B | $11.24B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $72.29 |
52-Week Low | $262.80 | $43.31 |
Enterprise Value | $247.47B | $11.32B |
Dividend Yield | 2.72% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $274.48, down 0.64% for the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $3.41. Revenue grew to $26.89 billion in 2025, supported by a net income margin of 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and customer experience improvements.
The outlook remains positive with a consensus price target of $322.45, implying significant upside. Strong fundamentals and analyst buy ratings (59.68%) support growth, though risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock offers a solid dividend yield with recent payouts of $1.86 per share.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
